Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37232, USA.
Vanderbilt Biophotonics Center, Vanderbilt University, Nashville, TN, 37232, USA.
Sci Rep. 2021 Nov 9;11(1):21945. doi: 10.1038/s41598-021-01544-4.
Ovarian cancer has a poor cure rate and rates of relapse are high. Current recurrence detection is limited by non-specific methods such as blood testing and ultrasound. Based on reports that human epididymis four (HE4) / creatinine (CRE) ratios found in urine are elevated in ovarian cancers, we have developed a paper-based device that combines lateral flow technology and cell phone analysis to quantitatively measure HE4/CRE. Surrogate samples were used to test the performance over clinically expected HE4/CRE ratios. For HE4/CRE ratios of 2 to 47, the percent error was found to be 16.0% on average whether measured by a flatbed scanner or cell phone. There was not a significant difference between the results from the cell phone or scanner. Based on published studies, error in this method was less than the difference required to detect recurrence. This promising new tool, with further development, could be used at home or in low-resource settings to provide timely detection of ovarian cancer recurrence.
卵巢癌的治愈率较低，复发率较高。目前的复发检测受到血液检测和超声等非特异性方法的限制。基于尿液中发现的人附睾蛋白 4（HE4）/肌酐（CRE）比值在卵巢癌中升高的报告，我们开发了一种基于纸张的设备，该设备结合了侧流技术和手机分析，可定量测量 HE4/CRE。使用替代样本来测试在临床预期 HE4/CRE 比值范围内的性能。对于 HE4/CRE 比值为 2 到 47 的情况，通过平板扫描仪或手机测量时，平均误差为 16.0%。手机和扫描仪的结果之间没有显着差异。根据已发表的研究，该方法的误差小于检测复发所需的差异。这种有前途的新工具，如果进一步开发，可以在家中或资源有限的环境中使用，以提供对卵巢癌复发的及时检测。
